



96th SCIENTIFIC COMMITTEE PLENARY

Meeting date:	4-5 December 2019
Meeting hours:	9.00-18:45 9.00-13.30
Meeting venue:	EFSA Auditorium
Chair:	Simon More

Agenda

No.	Topic
1	Welcome and Apologies for absence
2	Adoption of the agenda
3	Declarations of Interest
4	Scientific outputs submitted for information/ discussion/ possible endorsement
4.1	Draft report on "Requirements for whole genome sequence analysis of microorganisms intentionally used in the food chain". EFSA-Q-2019-00434 For discussion and possible endorsement
4.2	Draft Guidance (chapter 4.2) on appraising and integrating evidence from epidemiological studies. EFSA-Q-2019-00199 – For discussion
4.3	Draft framework for protocol development for EFSA's non-application scientific assessments. EFSA-Q-2019-00265 – For endorsement for testing phase
4.4	Draft guidance on aneugenicity assessment. EFSA-Q-2019-00262 – for discussion
4.5	Implementation of the guidance on uncertainty in scientific assessment (link here) in REPRO Department - for information and discussion
4.6	Draft opinion "Evaluation of existing guidelines for their adequacy to the molecular characterisation and environmental risk assessment of genetically modified microorganisms obtained through synthetic biology." EFSA-Q-2018-00921 – For preliminary discussion

4.7	<p>Draft technical reports on mixtures:</p> <ul style="list-style-type: none"> - Human risk assessment of multiple chemicals using component-based approaches: a horizontal perspective. EFSA-Q-2016-00537 - Towards harmonised methodologies for the risk assessment of multiple chemicals in bee species. EFSA-Q-2018-00670 <p>For information</p>
5	Feedback from the Scientific Committee/Scientific Panels, EFSA, the European Commission
5.1	<p>Feedback from Panels</p> <ul style="list-style-type: none"> - Challenges in the implementation of SC cross cutting guidance (Nano, BMD etc) - Methodologies development - Risk assessment with cross-cutting issues
5.2	<p>Update on WGs activities</p> <ul style="list-style-type: none"> - Cross-cutting WG Nano - Cross-cutting WG Benchmark Dose (BMD) - Cross-cutting WG Mixtox 2 - Cross cutting WG Genotoxicity - Cross-cutting WG Uncertainty - WG Non Monotonic Dose Response (NMDR) - WG Health Based Guidance Values (HBGV) - WG Bees Wax - WG MUST-B - WG on Compendium of botanicals
6	Other topics for information and discussion
6.1	<p>Looking ahead:</p> <ul style="list-style-type: none"> - Update on EFSA Strategy 2021-2027 - Update on the future of risk assessment in EFSA <p>For information and discussion</p>
6.2	Developmental neurotoxicity (DNT) in the EFSA outlook
6.3	<p>Proposal for the amendment of the “emerging risk” definition</p> <p>For discussion and possible endorsement</p>
7	Any other business
<i>End of the meeting</i>	